



C-P-1646  
Attn:  
IDS  
Wallace  
H/S  
1/15/00

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson

ELI LILLY AND COMPANY

Date 1-11-2000

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 19 2000

Applicants	:	Thomas Frank Bumol, et al.	)	
Serial No.	:	09/280,567	)	
Filed	:	March 30, 1999	)	Group Art Unit: 1646
For	:	THERAPEUTIC APPLICATIONS OF mFLINT POLYPEPTIDES	)	Examiner: Unassigned
Docket No.	:	X-12915	)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Thomas D. Webster, Ph.D.  
Attorney for Applicants  
Registration No. 39,872  
Phone: 317-276-3334

Eli Lilly and Company  
Patent Division/TDW  
Lilly Corporate Center  
Indianapolis, IN 46285

January 11, 2000